SAFESCIENCE INC
8-K, EX-99.1, 2000-10-26
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: SAFESCIENCE INC, 8-K, 2000-10-26
Next: CROWN PAPER CO, 8-K, 2000-10-26





Contacts:

Rick Pierce                                        Douglas MacDougall
V.P., Finance & Investor Relations                 Chris Erdman
SafeScience, Inc.                                  Feinstein Kean Healthcare
(617) 422-0674                                     (617) 577-8110
www.safescience.com                                 www.fkhealth.com
-------------------                                 ----------------

FOR IMMEDIATE RELEASE
---------------------

            U.S. ENVIRONMENTAL PROTECTION AGENCY APPROVES CONDITIONAL
                  REGISTARATION OF ELEXA-4(R)FROM SAFESCIENCE

    SAFESCIENCE ANTICIPATES ACTIVE MARKETING OF PLANT DEFENSE BOOSTER FOR THE
                               2001 GROWING SEASON

BOSTON, MA, OCTOBER 20, 2000--  SafeScience,  Inc.,  (Nasdaq,  SAFS),  announced
today  that the  United  States  Environmental  Protection  Agency's  Office  of
Pesticide Programs,  Biopesticides and Pollution Prevention Division has granted
conditional  approval  of  its  Elexa-4  Plant  Defense  Booster.  Elexa-4  is a
non-toxic,  Plant Defense Booster that helps protect grapes,  strawberries and a
wide variety of other crops from pathogens such as powdery mildew, boytritis and
gray mold.  Elexa  stimulates  the plant's own natural  defense system to defend
against attack by these diseases.

"Elexa-4  addresses  large and  important  agricultural  markets and we are very
pleased by the  conditional  EPA approval for Elexa-4,"  stated Richard  Daoust,
Ph.D.  Vice President of Agriculture  of  SafeScience.  "While we will initially
focus  our sales  efforts  for  Elexa-4  on  high-value  crops  such as  grapes,
strawberries,  cherries,  and  roses  in the  United  States,  Elexa-4  has been
approved for use on a variety of both commercial  high-value and commodity crops
such as tree fruits,  tomatoes,  melons,  cucumbers,  and greenhouse and nursery
plants."

"We  have  filed  for  state  registration  in  California  and  will  now  file
registrations   for  Elexa-4  in  other  states.   Subject  to  receiving  state
registration SafeScience can begin sales of Elexa-4.  SafeScience will be filing
additional  information  to comply with the EPA  registration  process to obtain
full  approval,  which it expects to receive  within six months.  "We anticipate
actively  marketing  Elexa-4 for the Spring 2001 growing season,"  continued Dr.
Daoust.  "Elexa-4 has been produced in commercial scale and the finished product
is being held in inventory for sale pending final state registration  approvals.
The product  will be priced  competitively  with other  registered  chemical and
biological pest control solutions and is easily manufactured and scaleable."

Elexa-4 is considered  "exempt from  tolerance" by the EPA,  which means that it
does not leave chemical  residues on fruit or foliage.  Elexa-4's  exempt status
allows it to be  applied  up to and on the day of  harvest  unlike  conventional
pesticides  that  must be  discontinued  weeks in  advance.  Elexa  has been and
continues to be field  tested on a variety of crops in the United  States and in


                                     -more-

<PAGE>


                                                                          Page 2


other countries  against important  commercial  diseases such as powdery mildew,
downey mildew, gray mold and other diseases.  Several research trials show Elexa
to be as effective  against certain important  commercial  diseases as currently
used traditional  commercial  chemical  fungicides.  Additional field trials are
ongoing.

Elexa-4 was recently  cited in two trade  journals,  the January 2000 edition of
The Grape  Grower,  Magazine  of the  Western  Grape  Industry  and the May 2000
edition of the American Fruit Grower. Both publications discuss the scope of the
Food Quality  Protection  Act and the fact that current  concerns  with chemical
resistance by pests to commonly used toxic  pesticides  are changing the methods
U.S.  growers  use  to  control  these  pests.  This  regulatory  and  political
environment  makes newly approved  products like Elexa-4  potentially  important
components of many growers' future pest control programs.

According to published  literature,  the worldwide market for products  targeted
towards  prevention and treatment of plant fungal diseases is approximately  six
billion dollars.

SAFESCIENCE
SafeScience  develops and  licenses  pharmaceutical,  agricultural  and consumer
products.  The Company's human  therapeutic  products include GBC-590,  a unique
compound to treat cancer,  which is in Phase II human clinical  trials,  as well
as, an antifungal compound,  CAN-296, in pre-clinical  development for potential
treatment of human fungal  infections.  In the area of agriculture,  SafeScience
has received  conditional U.S. EPA approval of Elexa-4(R) Plant Defense Booster,
an innovative  compound  which  stimulates  the plant to protect  itself against
pathogens.  SafeScience has filed for state  registration of Elexa in California
and will now begin  the  process  of  registering  it in  several  U.S.  states.
SafeScience's line of consumer and commercial  products are being marketed under
the  SafeScience(R)  brand as an alternative to conventional  products employing
potentially harmful chemicals. Further information is available on SafeScience's
web site: http://www.safescience.com.
          --------------------------

SAFE HARBOR STATEMENT
Any statements  contained in this release that relate to future plans, events or
performance are forward-looking statements that involve risks and uncertainties,
including,  but  not  limited  to,  risks  of  product  nonapproval  or  product
development and market acceptance risks, the impact of competitive  products and
pricing,  the results of current and future  licensing  and other  collaborative
relationships,   the  results  of  financing  efforts,   developments  regarding
intellectual  property rights and litigation,  and other risks identified in the
Company's Securities and Exchange Commission filings.  Actual results, events or
performance  may differ  materially.  Readers are  cautioned  not to place undue
reliance  on these  forward-looking  statements,  which  speak  only as the date
hereof.  The Company undertakes no obligation to publicly release the results of
any revisions to these  forward-looking  statements  that may be made to reflect
events or  circumstances  after the date hereof or to reflect the  occurrence of
unanticipated events.

                                       ###




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission